

Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)

Technology appraisal guidance

Published: 23 July 2025

www.nice.org.uk/guidance/ta1084

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments in adults. This is because Bristol-Myers Squibb has confirmed that it does not intend to make an evidence submission for the appraisal. Bristol-Myers Squibb considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this population.

Information

If NHS organisations wish to consider idecabtagene vicleucel for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7125-1